Liu Hongbiao, Zhan Hongwei, Zhang Ying, He Gangqiang, Wang Hui, Zhang Qiaoxia, Zheng Lili
Department of Nuclear Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Diagnostics (Basel). 2021 Oct 6;11(10):1846. doi: 10.3390/diagnostics11101846.
The present retrospective study was designed to evaluate the relative diagnostic utility of breast-specific gamma imaging (BSGI) and breast magnetic resonance imaging (MRI) as means of evaluating female breast cancer patients in China.
A total of 229 malignant breast cancer patients underwent ultrasound, mammography, BSGI, and MRI between January 2015 and December 2018 for initial tumor staging. Of these patients, 73 were subsequently treated via definitive breast surgery following neoadjuvant chemotherapy (NAC), of whom 17 exhibited a complete pathologic response (pCR) to NAC.
BSGI and MRI were associated with 76.8% (43/56) and 83.9% (47/56) sensitivity (BSGI vs. MRI, = 0.341) values, respectively, as a means of detecting residual tumors following NAC, while both these approaches exhibited comparable specificity in this diagnostic context. The specificity of BSGI for detecting residual tumors following NAC was 70.6% (12/17), and that of MRI was 58.8% (10/17) (BSGI vs. MRI, = 0.473).
These results demonstrate that BSGI is a useful auxiliary approach to evaluating pCR to NAC treatment.
本回顾性研究旨在评估乳腺特异性伽马成像（BSGI）和乳腺磁共振成像（MRI）在中国评估女性乳腺癌患者方面的相对诊断效用。
2015年1月至2018年12月期间，共有229例恶性乳腺癌患者接受了超声、乳腺X线摄影、BSGI和MRI检查以进行初始肿瘤分期。其中，73例患者在新辅助化疗（NAC）后接受了确定性乳房手术治疗，其中17例对NAC表现出完全病理缓解（pCR）。
作为检测NAC后残留肿瘤的手段，BSGI和MRI的敏感性分别为76.8%（43/56）和83.9%（47/56）（BSGI与MRI相比，P = 0.341），而在这种诊断背景下，这两种方法表现出相当的特异性。BSGI检测NAC后残留肿瘤的特异性为70.6%（12/17），MRI的特异性为58.8%（10/17）（BSGI与MRI相比，P = 0.473）。
这些结果表明，BSGI是评估NAC治疗pCR的一种有用的辅助方法。
